{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-24-002122","form_type":"8-K","ticker":"ACOG","cik":"0001655923","company_name":"Alpha Cognition Inc.","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.991751+00:00","generated_at":"2026-05-31T15:44:22.047034+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Alpha Cognition gets FDA approval for ZUNVEYL to treat mild-to-moderate Alzheimer's","bullets":["FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease; second oral AD therapy approved this decade.","GI adverse events under 2% and no insomnia observed in bioequivalence studies, designed to bypass GI absorption.","Commercial availability planned in pharmacies nationwide starting Q1 2025.","CEO Michael McFadden called approval a major breakthrough; company targets tolerability issues leading to 55% discontinuation rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-24-002122","json":"https://secwatch.observer/filing/0001013762-24-002122.json","markdown":"https://secwatch.observer/filing/0001013762-24-002122.md","text":"https://secwatch.observer/filing/0001013762-24-002122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655923/000101376224002122/0001013762-24-002122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655923/000101376224002122/ea0210215-8k_alpha.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:44:22.047034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}